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Background
Clinical and epidemiological data have identified a cardi-
orenal syndrome (CRS), in which heart and/or kidney
failure accelerates dysfunction in the other organ. New
therapeutics are needed to target the mechanisms that
cause CRS and treat the whole patient. The aims of this
study were to 1) assess in vivo cardiorenal metabolism
using hyperpolarized 13C MR spectroscopy (MRS) in
experimental CRS, and 2) to test the hypothesis that
normalizing aberrant metabolic reprogramming could
provide CRS therapy.
Methods
The diabetic Goto-Kakizaki [GK] rat, aged to 40 weeks,
were used as a model of secondary CRS and compared
with age matched Wistar controls. Animals underwent
echocardiography at 8 weeks of age, and subsequently
every 4 weeks. A cohort of paired animals (n = 5) under-
went invasive cardiac catheterization for pressure-volume
(PV) loop analysis. In a second cohort of animal pairs (n =
4), hyperpolarized [1-13C]pyruvate was infused intrave-
nously and 13C MR spectroscopic data were acquired from
hearts and kidneys. An interleaved pulse-acquire pulse
sequence was used (1.2 cm axial slice through alternately
heart or kidneys, 20° tip angle, TR=1 s). Daily treatment
with glucagon-like peptide-1 (GLP-1) receptor agonist lira-
glutide (0.2 mg/kg) was given to a third cohort GK rats for
10 weeks (n = 4) prior to 13C MRS assessment of metabo-
lism. Cardiac and renal tissue was collected for histopatho-
logical and molecular analysis.
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Figure 1 Left Representative series of MR spectra acquired from the heart of a diabetic rat, following infusion of hyperpolarized [1-
13C]pyruvate, and the corresponding quantification (middle and right). The input bolus of pyruvate is evident, as are its enzymatic
conversions to other metabolites and the decay of the hyperpolarized signal. Data are expressed as ratios of each observed metabolite to the
total observed 13C metabolicm, which did not change with diabetes or liraglutide treatment. Hyperpolarised 13C MRS data were obtained from
the kidneys during the same [1-13C]pyruvate infusion, with spectra acquired in between cardiac spectra (a 1 s offset).
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Results
Glycated hemoglobin (HbA1c) confirmed that GK rats
were diabetic at 20 weeks. Forty-week-old untreated GK
rats developed proteinuria, LV hypertrophy, and pulmon-
ary congestion. PV-loops demonstrated preserved systolic,
yet impaired diastolic function. Histology demonstrated
myocyte and glomerular hypertrophy, interstitial fibrosis
and glomerulosclerosis. Hyperpolarised 13C MRS data
indicated that cardiorenal carbohydrate metabolism was
reprogrammed to promote lactate production over oxida-
tion (Figure 1). In the kidney, 13C-lactate was increased at
the expense of 13C-alanine. Metabolic reprogramming was
likely mediated by inflammation (in both organs, macro-
phage infiltration and toll like receptor 4 protein expres-
sion were increased) or maladaptive systemic
gluconeogenesis (renal Pck1 and G6pc mRNA were
increased). Liraglutide treatment reduced HbA1c levels in
GK rats by 13%. The drug normalized carbohydrate utili-
zation to abrogate 13C-lactate production in the heart
(Figure 1). In the kidney, no effect of liraglutide treatment
was observed.
Conclusions
Hyperpolarized 13C MRS identified that in diabetes-
induced CRS, whole-body carbohydrate utilization was
impaired and represented a novel target for therapy. We
conclude that 1) non-invasive metabolic assessment using
hyperpolarized 13C MRS offers an important tool to inves-
tigate the pathology of multi-organ diseases, and to iden-
tify and evaluate new therapeutic approaches, and 2) that
liraglutide therapy may have a role in treating diabetes-
induced CRS by preserving myocardial function.
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